Skip to main content

Advertisement

Table 1 Circulating microparticles (MP) in patient with APL (day 20) and in STEMI patients without APL (n = 9, day 5).

From: Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis

  Circulating procoagulant microparticles (nM PhtdSer Eq.)
  STEMI patient with APS STEMI patients without APL (n = 9) Healthy Volunteers (n = 50)
MP captured onto annexin V 21 9.7 ± 1.5 2.3 ± 0.1
MP of platelet origin (captured onto anti GPIb antibody) 7.70 1.32 ± 0.18 0.58 ± 0.1
MP of endothelial origin (captured onto anti CD31 antibody) 0.50 0.17 ± 0.05 0.02 ± 0.006
  1. Microparticles were captured onto insolubilized annexin V or on anti GPIb and anti CD31 antibodies to identify the respective contribution of platelet and endothelial-derived MP. MP catalytic phospholipid content was measured by prothombinase assay as nM Phosphatidylserine equivalents (PhtdSer Eq.). All STEMI patients were treated by PTCA, under abciximab coverage. No direct comparison between levels of MP captured onto annexin V and antibodies can be performed because affinities for the respective ligands are certainly different.